Greg Moeck

VenatoRx Pharmaceuticals (United States)

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 7 papers. Top paper: “Establishing the reference broth microdilution MIC method for cefepime-taniborbactam”.

Establishing the reference broth microdilution MIC method for cefepime-taniborbactam

Journal of Clinical Microbiology(2025)10.1128/jcm.00661-25

N/A

0.236DataRank · unranked

3 citations

Susan M. Cusick, D.C. Pevear, Laura Koeth, Jeanna DiFranco-Fisher, Nimmi Kothari +3 more

Examining the activity of cefepime-taniborbactam against Burkholderia cepacia complex and Burkholderia gladioli isolated from cystic fibrosis patients in the United States

Antimicrobial Agents and Chemotherapy(2023)10.1128/aac.00498-23

N/A

0DataRank · unranked

6 citations

Elise T. Zeiser, Scott A. Becka, John J. LiPuma, David A. Six, Greg Moeck +2 more

Cefepime–taniborbactam activity against antimicrobial-resistant clinical isolates of Enterobacterales and Pseudomonas aeruginosa: GEARS global surveillance programme 2018–22

Journal of Antimicrobial Chemotherapy(2024)10.1093/jac/dkae329

N/A

0DataRank · unranked

24 citations

Mark G. Wise, Meredith Hackel, David A. Six, Tsuyoshi Uehara, Denis M. Daigle +4 more

Discovery of VNRX-7145 (VNRX-5236 Etzadroxil): An Orally Bioavailable β-Lactamase Inhibitor for Enterobacterales Expressing Ambler Class A, C, and D Enzymes

Journal of Medicinal Chemistry(2021)10.1021/acs.jmedchem.1c00437

N/A

0DataRank · unranked

47 citations

Allison L. Zulli, Eugen F. Mesaros, Randy W. Jackson, Steven A. Boyd, Bin Liu +13 more

ARGONAUT-IV: susceptibility of carbapenemase-producing Klebsiella pneumoniae to the oral bicyclic boronate β-lactamase inhibitor ledaborbactam combined with ceftibuten

Antimicrobial Agents and Chemotherapy(2024)10.1128/aac.01127-24

N/A

0DataRank · unranked

6 citations

Caryn E. Good, Ayman M. Abdelhamed, Andrew R Mack, Christopher R. Bethel, Steven H. Marshall +12 more

ARGONAUT-IV: susceptibility of carbapenemase-producing Klebsiella pneumoniae to the oral bicyclic boronate β-lactamase inhibitor ledaborbactam combined with ceftibuten.

UNC Libraries(2025)10.17615/tde0-ye85

N/A

0DataRank · unranked

0 citations

Vance G. Fowler, Daniel D. Rhoads, Andrea M. Hujer, Robert A Bonomo, Christopher R. Bethel +12 more

ARGONAUT-III and -V: susceptibility of carbapenem-resistant Klebsiella pneumoniae and multidrug-resistant Pseudomonas aeruginosa to the bicyclic boronate β-lactamase inhibitor taniborbactam combined with cefepime

Antimicrobial Agents and Chemotherapy(2024)10.1128/aac.00751-24

N/A

0DataRank · unranked

14 citations

Ayman M. Abdelhamed, Caryn E. Good, Andrew R Mack, Christopher R. Bethel, Steven H. Marshall +12 more